Penetration of dynorphin 1-13 across the blood-brain barrier

Neuropeptides

Volumn 32, Issue 2, 1998, Pages 141-149

  Turner, T D ^a   Browning, J L ^a   Widmayer, M A ^a   Baskin, D S ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYNORPHIN[1-13];

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CAT; CEREBELLUM; CONTROLLED STUDY; HIPPOCAMPUS; ISOTOPE LABELING; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; TISSUE DISTRIBUTION;

ANIMALIA; FELIDAE; FELIS CATUS; TRITIUM;

EID: 0031948706     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(98)90029-4     Document Type: Article

References (42)

1. Chavkin C, James I F, Goldstein A. Dynorphin is a specific endogenous ligand of the κ opioid receptor. Science 1982; 215: 413-415.
2. McKnight A T, Rees D C. Opioid receptors and their ligands. Neurotransmissions 1990; 7: 1-6.
3. Pardridge W M. Mechanisms of neuropeptide interaction with the blood-brain barrier. Ann NY Acad Sci 1986; 481: 231-249.
4. Baskin D S, Hosobuchi Y, Loh H H, Lee N M. Dynorphin 1-13 improves survival in cats with focal cerebral ischemia. Nature 1984; 312: 551-552.
5. Baskin D S, Kuroda H, Hosobuchi Y, Lee N M. Treatment of stroke with opiate antagonists - effects of exogenous antagonists and dynorphin 1-13. Neuropeptides 1985; 5: 307-310.
6. Baskin D S, Widmayer M A, Browning J L, Heizer M L, Schmidt W K. Evaluation of delayed treatment of focal cerebral ischemia with three selective kappa opioid agonists in the cat. Stroke 1994; 25: 2047-2053.
7. Baskin D, Kieck C, Hosobuchi Y. Naloxone reversal and morphine exacerbation of neurologic deficits secondary to focal cerebral ischemia in baboons. Brain Res 1984; 290: 289-296.
8. Banks W A, Kastin A J. Saturable transport of peptides across the blood-brain barrier. Life Sci 1987; 41: 1319-1338.
9. Banks W A, Kastin A J, Michals E A. Tyr-MIF-1 and metenkephalin share a saturable blood-brain barrier transport system. Peptides 1987; 8: 899-903.
10. Banks W A, Kastin A J, Michals E A, Barrera C M. Stereospecific transport of Try-MIF-1 across the blood-brain barrier by peptide transport system-1. Brain Res Bull 1990; 25: 589-592.
11. Kastin A J, Nissen C, Schally A V, Coy D H. Blood-brain barrier, half-time disappearance, and brain distribution for labeled enkephalin and a potent analong. Brain Res Bull 1976; 1: 583-589.
12. 5-enkephalin and their N-terminal amino acid (tyrosine). Brain Res 1985; 336: 125-132.
13. 1]-peptide T-amide is transported from blood to brain by a saturable system. Brain Res Bull 1987; 19: 629-633.
14. Woods S C, Porte D Jr. The central nervous system, pancreatic hormones, feeding, and obesity. Adv Metabolic Disorders 1978; 9: 283-312.
15. 35S]-Cycteine in rat brain after arterial injection. Res Commun Chem Pathol Pharmacol 1982; 37: 155-158.
16. Oldendorf W H. Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res 1970; 24: 372-376.
17. Tseng L F. Release of a dynorphin A (1-8) degrading enzyme from the spinal cord by intraventricular morphine in the rat. Life Sci 1988; 42: 1287-1293.
18. O'Brien M D, Waltz A G. Transorbital approach for occluding the middle cerebral artery without craniectomy. Stroke 1973; 4: 201-206.
19. Duffy K R, Pardridge W M. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987; 420: 32-38.
20. 99mTc]pertechnetate distribution in the head. J Appl Physiol 1993; 74: 2886-2895.
21. Graffinried B V, Pozo E D, Roubicek J et al. Effects of the synthetic enkephalin analogue FK 33-824 in man. Nature 1978; 272: 729-730.
22. Hruska R E, Pitman K T, Silbergeld E K, Ludmer L M. Prolactin increases the density of striatal dopamine receptors in normal and hypophysectomized male rats. Life Sci 1981; 30: 547-553.
23. Rapoport S I, Klee W A, Pettigrew K D, Ohno K. Entry of opioid peptides into the central nervous system. Science 1986; 207: 84-86.
24. Zlokovic B V, Begley D J, Djuricic B M, Mitrovic D M. Measurement of solute transport across the blood-brain barrier in the perfused guinea pig brain: method and application to N-Methyl-α-aminoisobutyric acid. J Neurochem 1986; 46: 1444-1451.
25. Young E A, Walker J M, Houghten R, Akil H. The degradation of dynorphin A in brain tissue in vivo and in vitro. Peptides 1987; 8: 701-707.
26. Davson H. The blood-brain barrier. J Physiol 1976; 255: 1-28.
27. Segal M B, Zlokovic B V. The blood-brain barrier, amino acids and peptides. Dordrecht: Kluwer Academic Publishers, 1990.
28. 14C]sucrose in rats. Brain Res 1992; 569: 330-335.
29. 14C]sucrose. Brain Res 1986; 377: 286-291.
30. Ziylan Y Z, Lefauconnier J M, Bernard G, Bourre J M. Blood-brain barrier permeability: regional alterations after acute and chronic administration of ethinyl estradiol. Neurosci Lett 1990; 118: 181-184.
31. Muller S, Grundy B L, Hocchaus G. Metabolism of dynorphin A1-13 in human CSF. Neurochem Res 1996; 21: 1213-1219.
32. Kovacs Z, Ikezaki K, Samoto K, Inamura T, Fukui M, VEGF and fit - expression time kinetics in rat brain infarct. Stroke 1996; 27: 1865-1872.
33. Strugar J, Rothbart D, Harrington W, Criscuolo G R. Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis. J Neurosurg 1994; 81: 560-566.
34. Hatashita S, Hoff J T. Brain edema and cerebrovascular permeability during cerebral ischemia in rats. Stroke 1990; 21: 582-588.
35. Shigeno T, Asano T, Mima T, Takakura K. Effect of enhanced capillary activity on the blood-brain barrier during focal cerebral ischemia in cats. Stroke 1989; 20: 1260-1266.
36. Astrup J, Siesjö B K, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981; 12: 723-725.
37. Baskin D S, Browning J L. Opioid peptides in focal cerebral ischemia in the cat. Soc Neurosci Abstr 1988; 14: 1065.
38. Fried R L, Nowak T S, Jr. Opioid peptide levels in gerbil brain after transient ischemia: lasting depletion of hippocampal dynorphin. Stroke 1987; 18: 765-770.
39. Birch P J, Rogers H, Hayes A G. Neuroprotective actions of GR89696, a highly potent and selective K-opioid receptor agonist. Br J Pharmacol 1991; 103: 1819-1823.
40. Hall E D, Pazara K E. Quantitative analysis of effects of κ-opioid agonists on post-ischemic hippocampal CA1 neuronal necrosis in gerbils. Stroke 1988; 19: 1008-1012.
41. Tang A H, Silvia R C. Protection from cerebral ischemia by U-50, 488 in cats subjected to occlusion of the middle cerebral artery. Soc Neurosci Abstr 1986; 12: 64.
42. Heron A, Traiffort E, Affix M, Dimitriadou V, Schwartz J C. Prodynorphin mRNA expression in the rat dentate gyrus after cerebral ischemia. Neuropeptides 1996; 30: 355-358.